PAUL L BERNS
CIK 1202769 · See Remarks · last filed 2026-06-24
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$26.93M
Companies
13
Total Filings
100
Lifetime Open-Market Net
$121.97M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KARD | Director | 15,062,741 | — | — | $20.00M | 2 | 2026-06-24 |
| LYEL | 10%+ Owner | 910,317 | $13.92 | $12.67M | $112.50M | 1 | 2026-03-09 |
| NMRA | See Remarks | 7,528,282 | $1.62 | $12.23M | -$57.9K | 7 | 2026-02-19 |
| Metsera, Inc. (MTSR) Delisted | Director | 0 | $70.50 | $0 | $14.22M | 3 | 2025-11-13 |
| Unity Biotechnology, Inc. (UBX) Delisted | Director | 326 | $0.20 | $65 | $0 | 7 | 2024-06-21 |
| EQRx, Inc. (EQRXW) Delisted | Director | 0 | $0.05 | $0 | $0 | 4 | 2023-11-09 |
| JAZZ | Director | 8,290 | $244.34 | $2.03M | -$3.76M | 23 | 2021-08-09 |
| VYNE Therapeutics Inc. (MNLO) Delisted | Director | — | — | — | $0 | 2 | 2019-08-08 |
| Anacor Pharmaceuticals, Inc. (ANAC) Delisted | President and CEO | 0 | $10.19 | $0 | -$16.52M | 14 | 2016-06-24 |
| XENOPORT INC (XNPT) Delisted | Director | 15,000 | — | — | -$525.2K | 10 | 2016-05-19 |
| Cellectar Biosciences, Inc. (CLRB.Z) Delisted | Director | 117,371 | — | — | $248.8K | 1 | 2016-04-21 |
| Cellectar Biosciences, Inc. (CLRB.W) Delisted | Director | — | — | — | $0 | 2 | 2015-06-10 |
| ALLOS THERAPEUTICS INC (ALTH) Delisted | Chief Executive Officer | 0 | — | — | -$4.14M | 22 | 2012-09-05 |
Recent Filings · Page 5 of 10
100 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-02-05 | Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Grant (A) | +14,584 | $0 | EDGAR |
| 2016-01-05 | Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Sell (S) | −2,533 | -$284.6K | EDGAR |
| 2015-12-15 | Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Mixed | — | -$2.15M | EDGAR |
| 2015-09-25 | JAZZ | — | — | $0 | EDGAR |
| 2015-09-17 | Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Mixed | — | -$2.69M | EDGAR |
| 2015-08-17 | Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Mixed | — | -$2.67M | EDGAR |
| 2015-08-11 | JAZZ | Mixed | +509 | -$144.2K | EDGAR |
| 2015-06-10 | Cellectar Biosciences, Inc. (CLRB.W) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-05-21 | XENOPORT INC (XNPT) Delisted | Mixed | +5,000 | $0 | EDGAR |
| 2015-04-28 | Anacor Pharmaceuticals, Inc. (ANAC) Delisted | Mixed | −55,000 | -$3.18M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.